Login

VII ALBA Users' Meeting

3–4 Sept 2026
ALBA Synchrotron
Europe/Madrid timezone

Session

Life Sciences

4 Sept 2026, 11:00
ALBA Synchrotron

ALBA Synchrotron

Conveners

Life Sciences

  • Judith Juanhuix Gibert

Presentation materials

There are no materials yet.

  1. 126. Advancing life sciences research through multiscale X-ray phase-contrast tomography
    Elena Longo (Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy)
    04/09/2026, 11:00
    Oral contribution

    X-ray phase-contrast tomography provides a non-destructive 3D approach for the assessment of biomaterials and biological samples with high spatial and contrast resolution. Over the years, its ability to highlight tissue architecture and intricate material structures across multiple scales has been well-documented. By providing advanced morphological characterization, it is widely employed as a...

    Go to contribution page
  2. 91. An integrated cloud-based platform for synchrotron X-ray phase contrast imaging data analysis and clinical data management
    Mariana Lourenço Seabra (University Pompeu Fabra)
    04/09/2026, 11:30
    Oral contribution

    Synchrotron-based X-ray phase-contrast imaging (X-PCI) enables non-destructive, high-resolution three-dimensional visualisation of soft-tissue microstructure at sub-micron scales, offering unique insights into tissue organisation that are inaccessible with conventional histology [1]. However, the analysis and clinical interpretation of synchrotron datasets in research and clinical contexts...

    Go to contribution page
  3. 48. Structural elucidation of a dehalogenase designed with REXzyme: an encoder-decoder model trained on enzymatic reactions
    Dr Ramiro Illanes Vicioso (Centre of Genomic Regulation)
    04/09/2026, 11:50
    Oral contribution

    Per- and polyfluoroalkyl substances (PFAS) belong to a family of more than 4000 compounds known as “forever chemicals”; the high stability of C–F bonds hinders their degradation, hence their extensive spread and presence in the environment. PFAS have been related to a broad spectrum of medical conditions such as hypothyroidism, decreased antibody levels in neonates, or endometrial...

    Go to contribution page
  4. 60. Multimodal Imaging of Silica Nanoparticle Distribution: Impact of Concentration and Cell Doubling Time
    Isabella Scarpa (ALBA Synchrotron)
    04/09/2026, 12:10
    Oral contribution

    Silica nanoparticles (SiNPs) have emerged as promising nanoplatforms for both the diagnosis and treatment of diseases. A comprehensive understanding of nanoparticle–cell interactions is essential for advancing nanomedicine, yet most studies rely on static observations and lack volumetric information under near-native conditions. Among the factors influencing cellular uptake, the formation of...

    Go to contribution page
  5. 128. Movies of proteins at work — and why they’re harder to make than they look
    Tobias Weinert (Senior Scientist · Paul Scherrer Institute · Center for Life Sciences)
    04/09/2026, 12:30
    Oral contribution

    Proteins are machines, and machines are defined by what they do, not just what they look like. Yet almost everything we know about protein structure comes from snapshots: frozen moments from crystallography or cryo-EM, and now predicted scaffolds from AlphaFold. To understand how an enzyme interacts with a substrate, how a drug binds its target, or how a transporter pumps an ion, we need to...

    Go to contribution page
  6. 137. The future of life sciences at synchrotrons: going correlative, time-resolved, multi-scale. Joint discussion.
    Moderator: Judith Juanhuix (ALBA Synchrotron)
    04/09/2026, 13:00
Building timetable...